FOR IMMEDIATE RELEASE
Monday, September 29, 2003
Biomedical researchers in government, academia and industry have made tremendous progress working collaboratively towards developing countermeasures for bioterrorism, according to a report issued today on research funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health.
The NIAID Biodefense Research Agenda for CDC Category A Agents—Progress Report (PDF 1.9 MB) describes myriad steps the Institute has taken since February 2002 to catalyze the development of vaccines, treatments and diagnostics for the most threatening bioterror agents. It was in February 2002 that NIAID convened the first Blue Ribbon Panel on Bioterrorism and its Implications for Biomedical Research, which provided NIAID with objective expertise on the Institute’s biodefense future research plans and helped identify the highest priority areas.
“NIAID has greatly expanded its network of industry and academic partners in biodefense, and together they have made tremendous strides in a very short time towards developing countermeasures to protect all Americans from bioterrorism,” says Health and Human Services Secretary Tommy G. Thompson.
“The increased breadth and depth of biodefense research not only is helping us become better prepared to protect citizens against a deliberately introduced pathogen, it also is helping us tackle the continuous tide of naturally occurring emerging infections such as SARS and West Nile virus,” says NIAID Director Anthony S. Fauci, M.D.
The 37-page report covers progress on meeting the Blue Ribbon Panel’s research recommendations and progress in research on so-called Category A pathogens. The Centers for Disease Control and Prevention’s Category A agents are those that cause diseases considered to pose the greatest risk to national security: anthrax, smallpox, plague, botulism, tularemia and viral hemorrhagic fevers.
The progress report outlines specific actions NIAID has taken to prepare bioterror countermeasures. For example, the Institute has developed more than 50 initiatives to stimulate biodefense research, three-quarters of which are brand new. Through these initiatives, NIAID has greatly expanded its support of investigators in academia and partnerships with industry. It has also created new biodefense resources, taken advantage of genomic research advances, and furthered understanding of how microbes cause disease and how the immune system responds to infection.
Partnerships in Product Development
In addition to awarding contracts for second-generation smallpox and anthrax vaccines, NIAID has expanded other collaborative opportunities with industry. For example, the NIAID Biodefense Partnerships program is a new mechanism by which the Institute encourages private-sector research and development of countermeasures. Through this program and a similar initiative that includes academia—Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics and Diagnostics for Biodefense and SARS—NIAID is funding 31 grants to companies to develop high-priority biodefense products. In addition to attracting more pharmaceutical and biotechnology companies to infectious disease research, these awards will likely shorten the time from preclinical testing to commercialization of products.
NIAID recently awarded eight Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research. This nationwide network of multidisciplinary academic centers will conduct wide-ranging research on infectious diseases and the development of diagnostics, therapeutics and vaccines. In addition, through partnerships with other agencies and companies around the world, NIAID has made a significant investment in sequencing pathogen genomes. Researchers have sequenced genomes representative of all bacteria considered bioterror threats, and are sequencing genomes for at least one strain of every potential viral and protozoal bioterror pathogen. Finally, dozens of grants made to individual investigators at academic institutions nationwide are opening new avenues for improving our ability to prevent, diagnose and treat diseases caused by potential agents of terrorism.
Biodefense Research Resources and Facilities
NIAID is funding the construction of new biosafety laboratories around the country to address the serious shortage of such facilities to safely conduct research on biodefense and emerging infectious diseases. It also has developed and expanded contracts to screen new drugs; develop new animal models; establish a reagent and specimen repository; and provide researchers with genomic, proteomic and bioinformatic resources.
NIAID is funding research to better understand the body’s own protective mechanisms. In particular, one recent large-scale grant is funding sophisticated studies of the human innate immune system. Another new set of grants has established a network of researchers focused on studies of the human immune system and biodefense.
A complete description of NIAID’s biodefense research program is available online.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated September 29, 2003